Syschem (India)
BSE: SYSCHEM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Syschem (India)'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Syschem (India) Limited is a pharmaceutical and chemical manufacturer specialising in bulk drugs, active pharmaceutical ingredients (APIs), and chemical intermediates. The company also maintains a niche presence in specialty chemicals, industrial solvents, and the recovery and recycling of waste solvents.
Business Model
The company generates revenue through the contract manufacturing and supply of essential chemical building blocks for domestic and international pharmaceutical clients. It further enhances cost-efficiency and sustainability by providing solvent recovery and recycling services to industrial partners.
Growth Outlook
Growth is driven by the increasing demand for outsourced pharmaceutical intermediates and the expansion of its specialty chemical portfolio. The company's focus on sustainable solvent recycling provides a competitive advantage in an increasingly environmentally conscious regulatory landscape.
Key Risks
- Regulatory Compliance. The pharmaceutical and chemical manufacturing sectors are subject to stringent environmental and safety regulations that could impact operational continuity.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and solvents can significantly impact the company's profit margins.
- Market Competition. As a small-cap entity, the company faces intense competition from larger domestic and international players with greater economies of scale.
- Operational Concentration. Reliance on a single manufacturing facility in Haryana creates a risk of supply chain disruption in the event of local operational issues.
Start your research today
Unlock AI insights, financials, peers and live data on Syschem (India) and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · standalone
NET PROFIT
₹9 Cr
TTM · standalone
EPS
₹2.18
TTM · standalone
RETURN ON EQUITY
19.4%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
17.9%
TTM · standalone
P/E
19.5x
Q4 FY26 · standalone
EV/EBITDA
9.8x
Q4 FY26 · standalone
EBITDA MARGIN
9.8%
TTM · standalone
NET PROFIT MARGIN
0.5%
Q3 FY25 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Syschem (India)SYSCHEM | ₹167 Cr | 14.28 | 7.54 | -100.0% | 9.8% | 19.4% | 17.9% | -45.7% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Syschem (India)
BSE: SYSCHEM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Syschem (India)'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Syschem (India) Limited is a pharmaceutical and chemical manufacturer specialising in bulk drugs, active pharmaceutical ingredients (APIs), and chemical intermediates. The company also maintains a niche presence in specialty chemicals, industrial solvents, and the recovery and recycling of waste solvents.
Business Model
The company generates revenue through the contract manufacturing and supply of essential chemical building blocks for domestic and international pharmaceutical clients. It further enhances cost-efficiency and sustainability by providing solvent recovery and recycling services to industrial partners.
Growth Outlook
Growth is driven by the increasing demand for outsourced pharmaceutical intermediates and the expansion of its specialty chemical portfolio. The company's focus on sustainable solvent recycling provides a competitive advantage in an increasingly environmentally conscious regulatory landscape.
Key Risks
- Regulatory Compliance. The pharmaceutical and chemical manufacturing sectors are subject to stringent environmental and safety regulations that could impact operational continuity.
- Raw Material Price Volatility. Fluctuations in the cost of chemical feedstocks and solvents can significantly impact the company's profit margins.
- Market Competition. As a small-cap entity, the company faces intense competition from larger domestic and international players with greater economies of scale.
- Operational Concentration. Reliance on a single manufacturing facility in Haryana creates a risk of supply chain disruption in the event of local operational issues.
Start your research today
Unlock AI insights, financials, peers and live data on Syschem (India) and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · standalone
NET PROFIT
₹9 Cr
TTM · standalone
EPS
₹2.18
TTM · standalone
RETURN ON EQUITY
19.4%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
17.9%
TTM · standalone
P/E
19.5x
Q4 FY26 · standalone
EV/EBITDA
9.8x
Q4 FY26 · standalone
EBITDA MARGIN
9.8%
TTM · standalone
NET PROFIT MARGIN
0.5%
Q3 FY25 · standalone
Peers · Pharmaceuticals
As of Q4 FY26